Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) FCF Margin (2021 - 2025)

Historic FCF Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 38.81%.

  • Krystal Biotech's FCF Margin fell 317200.0% to 38.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.53%, marking a year-over-year increase of 220300.0%. This contributed to the annual value of 39.56% for FY2024, which is 2379900.0% up from last year.
  • As of Q3 2025, Krystal Biotech's FCF Margin stood at 38.81%, which was down 317200.0% from 52.92% recorded in Q2 2025.
  • Krystal Biotech's FCF Margin's 5-year high stood at 822.32% during Q1 2021, with a 5-year trough of 249.31% in Q3 2023.
  • For the 4-year period, Krystal Biotech's FCF Margin averaged around 81.26%, with its median value being 33.44% (2025).
  • Per our database at Business Quant, Krystal Biotech's FCF Margin surged by 3198400bps in 2024 and then plummeted by -317200bps in 2025.
  • Quarter analysis of 4 years shows Krystal Biotech's FCF Margin stood at 822.32% in 2021, then tumbled by -102bps to 18.81% in 2023, then soared by 407bps to 57.77% in 2024, then tumbled by -33bps to 38.81% in 2025.
  • Its FCF Margin was 38.81% in Q3 2025, compared to 52.92% in Q2 2025 and 28.08% in Q1 2025.